title: Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
abstract: OBJECTIVE
  The effect of topical miconazole oral gel and systemic oral voriconazole on the pharmacokinetics of oral etoricoxib was studied in 12 healthy volunteers.
  
  
  METHODS
  Plasma concentrations of etoricoxib, miconazole, voriconazole, and thromboxane B(2) generation were followed after ingestion of 60 mg etoricoxib without pretreatment, after topical administration of miconazole oral gel (85 mg x 3, 3 days), or after oral voriconazole (400 mg x 2, 1st day, 200 mg x 2, 2nd day).
  
  
  RESULTS
  Etoricoxib area under the plasma concentration-time curve (AUC(0-00)) and maximum plasma concentration (C(max)) geometric mean ratios (GMR) with/without miconazole were 1.69 {90% confidence interval (CI); 1.46-1.92} and 1.12 (90% CI; 0.99-1.25), respectively, and corresponding GMRs with/without voriconazole were 1.49 (90% CI; 1.37-1.61) and 1.19 (90% CI; 1.08-1.31), respectively.
  
  
  CONCLUSIONS
  Miconazole oral gel and oral voriconazole produced comparable increase in the exposure to etoricoxib, presumably via CYP3A inhibition.
authors.affiliation: Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itäinen Pitkäkatu 4B, 20520 Turku, Finland. vilhyn@utu.fi
authors.forename: Ville V
authors.initials: VV
authors.lastname: Hynninen
authors.forename: Klaus T
authors.initials: KT
authors.lastname: Olkkola
authors.forename: Pertti J
authors.initials: PJ
authors.lastname: Neuvonen
authors.forename: Kari
authors.initials: K
authors.lastname: Laine
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D001711:Biotransformation / Q000187:drug effects; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D000077613:Etoricoxib; D005782:Gels; D006801:Humans; D008297:Male; D008825:Miconazole / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D013450:Sulfones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013929:Thromboxane B2 / Q000097:blood; D014230:Triazoles / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D065819:Voriconazole; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D016861:Cyclooxygenase Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D005782:Gels; D011725:Pyridines; D011743:Pyrimidines; D013450:Sulfones; D014230:Triazoles; D013929:Thromboxane B2; D008825:Miconazole; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D065819:Voriconazole; D000077613:Etoricoxib
references.citation: Clin Pharmacokinet. 2006;45(7):649-63
references.pmid: 16802848
references.citation: J Chromatogr B Biomed Sci Appl. 2000 Oct 1;748(1):31-9
references.pmid: 11092584
references.citation: Drug Metab Dispos. 2002 Mar;30(3):314-8
references.pmid: 11854151
references.citation: Br Dent J. 2004 May 8;196(9):529-31
references.pmid: 15131616
references.citation: J Clin Pharmacol. 2003 Jun;43(6):573-85
references.pmid: 12817520
references.citation: Drug Metab Dispos. 2001 Jun;29(6):813-20
references.pmid: 11353749
references.citation: J Clin Pharmacol. 2003 Mar;43(3):268-76
references.pmid: 12638395
references.citation: Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:24-9
references.pmid: 14616410
references.citation: BMJ. 1997 Feb 1;314(7077):349
references.pmid: 9040331
references.citation: Clin Pharmacol Ther. 2006 Apr;79(4):362-70
references.pmid: 16580904
references.citation: Clin Pharmacol Ther. 1992 Jun;51(6):656-67
references.pmid: 1611805
references.citation: J Pharm Biomed Anal. 1998 Sep;17(8):1449-53
references.pmid: 9800664
references.citation: Thromb Haemost. 2000 May;83(5):794-5
references.pmid: 10823285
references.citation: Circulation. 2006 Apr 25;113(16):1950-7
references.pmid: 16618816
references.citation: J Chromatogr A. 2006 Nov 17;1134(1-2):143-50
references.pmid: 16989842
references.citation: J Chromatogr B Biomed Appl. 1996 Dec 13;687(2):453-6
references.pmid: 9017471
references.citation: Biol Pharm Bull. 2005 Sep;28(9):1805-8
references.pmid: 16141567
references.citation: Inflamm Res. 1996 Feb;45(2):68-74
references.pmid: 8907587
references.citation: Biol Pharm Bull. 2005 Sep;28(9):1813-6
references.pmid: 16141569
references.citation: J Clin Pharmacol. 2004 Oct;44(10):1125-31
references.pmid: 15342613
references.citation: Antimicrob Agents Chemother. 2003 Jul;47(7):2348-50
references.pmid: 12821496
references.citation: Clin Pharmacol Ther. 2006 Nov;80(5):502-8
references.pmid: 17112806
references.citation: Clin Ther. 2004 Jan;26(1):70-83
references.pmid: 14996519
references.citation: Drug Metab Dispos. 2003 Feb;31(2):224-32
references.pmid: 12527704